Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis To Payers: Entresto Works Or You Get A Discount

This article was originally published in Scrip

Executive Summary

Performance-based reimbursement agreements with US payers, like the deals that Novartis AG recently struck with Cigna Corp. and Aetna Inc. for the heart failure drug Entresto (sacubitril/valsartan), are rare, but Novartis US Head Christi Shaw said she's hopeful that the concept will catch on.

Advertisement

Related Content

Laying The Groundwork For Value-Based Healthcare In Europe
US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution
Medicare Risk-Sharing Contracts: A More Feasible Drug Cost Solution?
Merck/Aetna Pact Links Januvia Value-Based Payment To Treatment Intensification
AstraZeneca Groomed Paul Hudson For His New Role … At Novartis
Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume

Topics

Advertisement
UsernamePublicRestriction

Register

SC064468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel